



28th October 2026

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001
Scrip Code: 544250

National Stock Exchange of India Limited

C-1, Block G, Exchange Plaza,
Bandra-Kurla Complex,
Bandra East, Mumbai - 400 051
Symbol: SANOFICONR

Sub.: Outcome of Board Meeting held on Wednesday, 28th October 2026

Dear Sir/Madam,

We refer to our letter dated 22nd October 2026 informing you of our Board Meeting that was scheduled today. In this regard, we wish to inform you that the Board of Directors at its meeting held today i.e., Wednesday, 28th October 2026, *inter-alia* considered and approved the Unaudited Financial Results for the quarter and nine months ended 30th September 2026.

Further, pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we enclose herewith a copy of the Unaudited Financial Results for the quarter and nine months ended 30th September 2026, as approved at the aforesaid meeting, along with a copy of the Limited Review Report duly signed by the Statutory Auditors of the Company. In this regard, please also find enclosed the accompanying press release.

Extract of the aforesaid results will be published in the newspapers in the format prescribed under Regulation 47 of the SEBI Listing Regulations. The aforesaid financial results will also be available on the Company's website at <https://www.sanofi.com/en/india/consumer-healthcare/investors/financial-results>

The meeting of Board of Directors commenced at 2:45 p.m. and concluded at 4:30 p.m.

Kindly take the above information on record.

Thanking you.

Yours faithfully,

For Sanofi Consumer Healthcare India Limited

Nikunj Kumar
r Jaysukhlal
Savaliya
Digitally signed by
Nikunj Kumar
Jaysukhlal Savaliya
Date: 2026.10.28
18:16:04 +05'30'

Nikunj Kumar Savaliya
Company Secretary and Compliance Officer
Membership No.: F7048

Price Waterhouse & Co Chartered Accountants LLP

Review Report

To
The Board of Directors
Sanofi Consumer Healthcare India Limited
Unit 1104, 11th Floor, Godrej Two,
Pirojshanagar, Eastern Express Highway,
Vikhroli East, Mumbai 400 079.
Maharashtra, India

1. We have reviewed the unaudited financial results of Sanofi Consumer Healthcare India Limited (the “Company”) for the quarter ended September 30, 2026 and the year to date results for the period January 1, 2026 to September 30, 2026, which are included in the accompanying ‘Statement of unaudited financial results for the quarter and nine months ended September 30, 2026’ (the “Statement”). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations, 2015”), which has been digitally signed by us for identification purposes. The Statement is the responsibility of the Company’s Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Price Waterhouse & Co Chartered Accountants LLP, 252, Veer Savarkar Marg, Shivaji Park, Dadar (West)
Mumbai - 400 028
T: +91 (22) 66697508

Registered office and Head office: Plot No. 56 & 57, Block ON, Sector-V, Salt Lake, Kolkata - 700 091

Price Waterhouse & Co. (a Partnership Firm) converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-4362) with effect from July 7, 2014. Post its conversion to Price Waterhouse & Co Chartered Accountants LLP, its ICAI registration number is 304026E/E300009 (ICAI registration number before conversion was 304026E)

Price Waterhouse & Co Chartered Accountants LLP

5. (a) The financial results of the Company for the quarter ended September 30, 2025 and the year to date results for the period January 1, 2025 to September 30, 2025 were reviewed by another firm of Chartered Accountants who issued their unmodified conclusion, vide their report dated November 12, 2025.
- (b) The financial statements of the Company for the year ended December 31, 2025 were audited by another firm of Chartered Accountants, who issued an unmodified opinion vide their report dated February 25, 2026.

Our conclusion is not modified in respect of these matters.

For Price Waterhouse & Co Chartered Accountants LLP
Firm Registration Number: 304026E/ E-300009

ARUNKUMAR Digitally signed by
RAMDAS ARUNKUMAR RAMDAS
Date: 2026.10.28 18:00:13
+05'30'

Arunkumar Ramdas
Membership Number: 112433

UDIN: 26112433CIXTOW5773
Place: Mumbai
Date: October 28, 2026

Sanofi Consumer Healthcare India Limited

Registered Office : Unit 1104, 11th Floor, Godrej Two Pirojshanagar, Eastern Express Highway, Vikhroli East, Mumbai, Maharashtra, India, 400079
Corporate Identity Number: L21002MH2023PLC402652
Tel no: (91-22) 45288555
Website: www.sanofi.in Email: igrc.schil@sanofi.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2026

Particulars	(₹ in Million)					
	Quarter ended 30.09.2026 (Unaudited)	Quarter ended 30.06.2026 (Unaudited)	Quarter ended 30.09.2025 (Unaudited)	Nine Months ended 30.09.2026 (Unaudited)	Nine Months ended 30.09.2025 (Unaudited)	Year ended 31.12.2025 (Audited)
1. Revenue from Operations (Refer note 7)	2,631	2,357	2,339	7,280	6,274	8,784
2. Other Income	44	63	30	163	138	184
3. Total Income (1+2)	2,675	2,420	2,369	7,443	6,412	8,968
4. Expenses						
(a) Cost of Materials Consumed	407	475	365	1,284	1,108	1,607
(b) Purchases of stock in trade	116	160	260	457	641	702
(c) Changes in Inventories of stock in trade and finished goods	121	(72)	(7)	28	(131)	(8)
(d) Employee benefits expense	307	313	317	951	933	1,288
(e) Finance costs	3	4	6	12	15	20
(f) Depreciation and amortisation expense	31	33	33	96	83	117
(g) Other expenses	663	588	554	1,762	1,531	2,105
Total Expenses	1,648	1,501	1,528	4,590	4,180	5,831
5. Profit before exceptional item and tax (3-4)	1,027	919	841	2,853	2,232	3,137
6. Exceptional item (Refer note 4)	-	-	-	-	66	66
7. Profit before tax (5+6)	1,027	919	841	2,853	2,298	3,203
8. Tax expense						
Current Tax	266	234	225	741	579	820
Deferred Tax	(5)	(3)	(13)	(20)	(17)	(18)
9. Profit for the period/year (7-8)	766	688	629	2,132	1,736	2,401
10. Other comprehensive income (OCI)						
Items that will not be reclassified to the statement of profit and loss						
- Remeasurements of post-employment benefit obligations	(11)	-	-	(11)	-	(19)
- Income Tax impact relating to these items	3	-	-	3	-	5
11. Total comprehensive income for the period/year (9+10)	758	688	629	2,124	1,736	2,387
12. Paid-up equity share capital (Face Value of ₹ 10 per share)	230	230	230	230	230	230
13. Other equity	-	-	-	-	-	3,610
14. Basic and diluted earnings per share (not annualised) (in ₹)	33.26	29.87	27.31	92.57	75.38	104.27

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the review report dated October 28, 2026.

ARUNKUMAR RAMDAS
Digitally signed by
ARUNKUMAR RAMDAS
Date: 2026.10.28
18:00:37 +05'30'

Himanshu Bakshi
Digitally signed
by Himanshu
Bakshi
Date: 2026.10.28
17:43:38 +05'30'

Notes:

1. The above Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on October 28, 2026. The statutory auditors have carried out a limited review of the above results for the quarter and nine months ended September 30, 2026.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
3. In 2024, the Company had voluntarily decided to recall Combiflam Suspension, Allegra Suspension and Depura Kids from distributors, hospitals, and retailers as a precautionary measure. Subsequently, the Company had successfully relaunched Combiflam Suspension during the quarter ended June 2025 and Allegra Suspension and Depura Kids in quarter ended September 2025. Consequently, there were no sales of Combiflam Suspension, Allegra Suspension and Depura Kids in quarter ended March 31, 2025 and of Allegra Suspension and Depura Kids in quarter ended June 30, 2025. Hence, the results are not fully comparable with nine months of the previous year as the product recall and subsequent relaunches had an impact on the domestic business.
4. Exceptional item for nine months ended September 30, 2025 and year ended December 31, 2025 pertains to the reversal of ₹66 million related to demerger provisions made in 2024.
5. The Company has a single business segment namely 'Pharmaceutical Business'. Therefore, disclosure relating to segments under Ind AS 108 is not applicable and accordingly not made.
6. The Company does not have any subsidiary, associates or joint ventures as on September 30, 2026.
7. Revenue from operations includes sales of products and service income. Sales of products is as under:

₹ in Million

Particulars	Quarter ended (Unaudited)			Nine Months ended (Unaudited)		Year ended (Audited)
	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.12.2025
Sales of Product	2,438	2,132	2,132	6,634	5,715	8,045

Place: Mumbai
October 28, 2026

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the review report dated October 28, 2026.

ARUNKUMAR RAMDAS
Digitally signed by
ARUNKUMAR RAMDAS
Date: 2026.10.28
18:00:56 +05'30'

SANOFI CONSUMER HEALTHCARE INDIA LIMITED

Himanshu Bakshi
Managing Director

Himanshu Bakshi
Digitally signed
by Himanshu
Bakshi
Date: 2026.10.28
17:45:17 +05'30'

DIN: 08188412

Sanofi Consumer Healthcare India Limited reports Q3'26 Revenue at ₹2,631 MN, Net Profit at ₹1,027 MN

Highlights for the Quarter Y-O-Y:

- Revenue at ₹2,631 million, a growth of 12%
- Domestic Sales grew by 19%
- EPS grew by INR 5.95 (22%), driven by increase in revenue
- Profit Before Tax was up by 22%

Highlights for the nine months ended '26 Y-O-Y:

- Revenue from Operations at ₹7,280 million, a growth of 16%
- Domestic Sales grew by 15%; aided by relaunch
- Export Sales grew by 19%
- Profit Before Tax was up by 24%

Mumbai, 28 October 2026: Sanofi Consumer Healthcare India Limited (BSE:544250 | NSE: SANOFICONR) releases its financial results for the third quarter and nine months ended 2026, demonstrating profitable growth across key business segments. Revenue growth for the quarter stood at 12% year-on-year with domestic sales growing by 19%. Profit Before Tax (PBT) for Q3 '26 reached ₹1,027 million, an increase of 22% on a year-on-year basis. EPS grew by 22% year-on-year, supported by higher revenue and profitability during the quarter.

Commenting on the results, **Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India Limited**, *“Our Q3 performance reflects the disciplined execution of our strategy and the strength of our portfolio. We delivered healthy growth, driven by volume expansion and market share gains across key brands. Our investments in brand building and expanding our distribution footprint and Healthcare Professional reach are enabling us to serve more consumers.*

About Sanofi Consumer Healthcare India Limited (SCHIL):

Sanofi Consumer Healthcare India Limited (SCHIL) emerged as a distinct legal entity following its demerger from Sanofi India Limited on 1st June 2024. SCHIL operates independently, with a dedicated focus on the consumer healthcare sector. With an agile business model and legacy brands, SCHIL is one of the leading players in India's consumer healthcare market. Leveraging its global experience, SCHIL aims to enhance consumer wellbeing through its product portfolio encompassing Allergy Management, Digestive Wellness, Pain Care and Multivitamins. SCHIL's key brands include Allegra®, DePURA®, Avil® and Combiflam®. These brands are dedicated to building a healthier future by empowering people to take control of their health, through simplifying self-care and by addressing their everyday health concerns.

Contacts for Media Relations:

Clayton Dsouza | +91 9930011602 | claytond@avianwe.com
Shrutika Sukhi | +91 9167971057 | shrutikas@avianwe.com